Cardiol Therapeutics (STU:CT9) Institutional Ownership: 0.07% (As of Jul. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CT9 Cardiol Therapeutics Inc STU:CT9
38 GF Score
Price €1.04
! 3 Warning Signs
View Full Analysis

What is Cardiol Therapeutics Institutional Ownership?

Cardiol Therapeutics STU:CT9 +3.78% 38 Institutional Ownership is 0.07% as of Jul. 31, 2026. GuruFocus rates STU:CT9 with a GF Score™ of 38/100. The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cardiol Therapeutics's institutional ownership is 0.07%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cardiol Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cardiol Therapeutics's Float Percentage Of Total Shares Outstanding is 97.38%.

Cardiol Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Cardiol Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiol Therapeutics Institutional Ownership Chart

Cardiol Therapeutics Historical Data

The historical data trend for Cardiol Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 1.57 1.57 1.57 1.56 1.41 0.87 0.09 0.10 0.07 0.07
STU:CT9
38GF Score
Cardiol Therapeutics Inc STU:CT9
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiol Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.07% mean?
Cardiol Therapeutics (STU:CT9) has a Institutional Ownership of 0.07% as of Jul. 31, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cardiol Therapeutics and its competitors.
Is Cardiol Therapeutics' Institutional Ownership too high?
Cardiol Therapeutics' current Institutional Ownership is 0.07%. Overall, Cardiol Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Cardiol Therapeutics' Institutional Ownership compare to ZTS?
Cardiol Therapeutics' Institutional Ownership of 0.07% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cardiol Therapeutics and its competitors. Cardiol Therapeutics's current Institutional Ownership is 0.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiol Therapeutics stock overvalued right now?
Cardiol Therapeutics (STU:CT9) has a current Institutional Ownership of 0.07%. The current Institutional Ownership is 0.07%. Cardiol Therapeutics' overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Cardiol Therapeutics (STU:CT9), the current Institutional Ownership is 0.07% as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiol Therapeutics Business Description

Other Exchanges CRDL:USACRDL:Canada
Address 2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
38GF Score

Get the complete analysis for STU:CT9

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.04
Price